Intelligent Bio Solutions Says It Completed 135-Participant Method Comparison Study, Concluding All Clinical Data Collection For FDA 510(k) Submission Targeted In H2 2026

Benzinga Newsdesk www.benzinga.com Neutral 55.6%

Neg 0% Neu 55.6% Pos 0%

Comments

No comments yet. Be the first!